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Abstract
Rift Valley fever virus (RVFV) is a major human and animal pathogen associated with severe disease including hemorrhagic
fever or encephalitis. RVFV is endemic to parts of Africa and the Arabian Peninsula, but there is significant concern regarding
its introduction into non-endemic regions and the potentially devastating effect to livestock populations with concurrent
infections of humans. To date, there is little detailed data directly comparing the host response to infection with wild-type
or vaccine strains of RVFV and correlation with viral pathogenesis. Here we characterized clinical and systemic immune
responses to infection with wild-type strain ZH501 or IND vaccine strain MP-12 in the C57BL/6 mouse. Animals infected with
live-attenuated MP-12 survived productive viral infection with little evidence of clinical disease and minimal cytokine
response in evaluated tissues. In contrast, ZH501 infection was lethal, caused depletion of lymphocytes and platelets and
elicited a strong, systemic cytokine response which correlated with high virus titers and significant tissue pathology.
Lymphopenia and platelet depletion were indicators of disease onset with indications of lymphocyte recovery correlating
with increases in G-CSF production. RVFV is hepatotropic and in these studies significant clinical and histological data
supported these findings; however, significant evidence of a pro-inflammatory response in the liver was not apparent.
Rather, viral infection resulted in a chemokine response indicating infiltration of immunoreactive cells, such as neutrophils,
which was supported by histological data. In brains of ZH501 infected mice, a significant chemokine and pro-inflammatory
cytokine response was evident, but with little pathology indicating meningoencephalitis. These data suggest that RVFV
pathogenesis in mice is associated with a loss of liver function due to liver necrosis and hepatitis yet the long-term course of
disease for those that might survive the initial hepatitis is neurologic in nature which is supported by observations of human
disease and the BALB/c mouse model.
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Introduction
Rift Valley fever virus (RVFV) (family Bunyaviridae, genus
Phlebovirus) is a highly pathogenic virus that can cause lethal
disease in both humans and ruminant animals. RVFV is classified
by the National Institute for Allergy and Infectious Diseases
(NIAID) as a category A priority pathogen and is a United States
Department of Agriculture (USDA) high priority pathogen. RVFV
is historically endemic in sub-Saharan Africa, but recent outbreaks
on the Arabian Peninsula have indicated an increased range for
this virus. A recent outbreak in South Africa (2010–May 2011)
resulted in over 250 laboratory confirmed cases with an
approximate case fatality rate of 11% [1]. RVFV is transmitted
primarily by Aedes mcintoshi mosquitoes, although the virus has been
detected in 23 species of mosquitoes [2]. Given the abundance of
Aedes spp. in the United States and in other parts of the world, the
potential introduction of RVFV into naı ¨ve populations is a very
serious agricultural and public health concern [3,4]. Effective
vaccines or therapeutic intervention are not commercially
available for prevention or treatment of Rift Valley fever (RVF)
in humans.
RVF outbreaks in human populations vary in size, intensity and
location with these parameters dependent upon rainfall and
mosquito abundance [5–7]. The largest recorded outbreak of RVF
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Patients present with general malaise (chills, headaches, joint pain
and nausea) and fever that is debilitating for a short period. A
small percentage (#1%) of patients present with severe manifes-
tations including encephalitis, retinal vasculitis, or hemorrhagic
fever. Mortality rates up to 20% have been reported in these cases
[9–12].
RVFV causes a much more catastrophic disease in ruminants
than is seen in humans, particularly in pregnant animals where
nearly 100% of RVFV infected ruminants abort their fetuses
[13,14]. The onset of human cases can often be predicted by
outbreaks of disease in animals [7,15].
Although there are currently no licensed vaccines or therapeu-
tics for RVFV infection in humans, several potential vaccines are
available and have been tested in animals and humans (www.
clinicaltrials.gov) [16–22]. One of the most promising is the live-
attenuated MP-12 vaccine [18] which was developed by the US
Army [23]. The MP-12 strain was developed by 12 serial passages
of the wild-type strain ZH548 in the presence of 5-fluorouracil to
generate a virus that was avirulent in pregnant ewes [22,23].
Further analysis of MP-12 found that it induced high titer
neutralizing antibodies in vaccinated ewes and protected vacci-
nated lambs from subsequent challenge with wild-type virus [24].
MP-12 has subsequently been found to be apathogenic in adult
mice [25]. The MP-12 vaccine is available to researchers through
the Special Immunizations Program at the US Army Medical
Research Institute of Infectious Diseases (USAMRIID) as part of
an on-going clinical trial (www.clinicaltrials.gov).
RVFV is a lipid-enveloped icosohedral virus [26–28] containing
a segmented, negative-sense, single-stranded RNA genome [29].
The genome consists of three segments: large (L), medium (M),
and small (S). The L segment encodes the viral polymerase, while
the M segment encodes 4 proteins: Gn and Gc, (surface
glycoproteins), NSm (non-structural protein) and a 78 kDa
protein. The S segment is ambisense and encodes for two
proteins: N (nucleocapsid) and NSs (non-structural protein) [29].
The NSs protein of wild-type virus has been shown to have type
I interferon (IFN) antagonist activity while this property is lacking
in the NSs protein of the RVFV mutant clone 13 which has an in-
frame deletion in the NSs gene [30,31]. Other than the potential
role of type I IFN in limiting disease [32–34], little else is known
about the host immune response to RVFV infection.
One study by Smith et al. examined pathogenesis in BALB/c
mice following wild-type virus challenge, focusing on viral titers in
tissues, types of infected cells and histopathological changes during
infection [35]. An additional recent study evaluated the gene
expression of IL-10, IFN-b and IFN-c over the course of wild-type
virus infection in juvenile BALB/c mice while utilizing gene array
to identify the significant upregulation of a number of immune
response genes in the liver of infected mice [33].
The study described here was developed with the intent of
characterizing the relationship between the host response and viral
pathogenicity in adult C57BL/6 mice following challenge with
either wild-type RVFV ZH501 or the attenuated vaccine strain
MP-12. Here we evaluated a large panel of cytokines and
chemokines in multiple tissues over the complete course of the
infection in addition to measuring a number of clinical parameters.
The ZH501 strain of RVFV was isolated during the same 1977
outbreak in Kenya as was ZH548 and a sequence comparison
indicates approximately 99% identity. We chose to use C57BL/6
mice for this study as this strain is biased toward a Th-1, or cell-
mediated, immune response, which is more typical in limiting viral
infection [36–42].
Our studies found a marked difference between the host
response to infection with wild-type RVFV and the attenuated
MP-12 vaccine strain. While neither virus caused overt changes in
body weight or temperature, changes in clinical parameters were
more profound in animals infected with wild-type virus than with
the vaccine strain. Histopathologic changes in animals infected
with the wild-type virus were more significant than those in mock
or MP-12 infected animals, including hepatocellular necrosis,
which correlated with the presence of viral antigen. Furthermore,
there was a significant cytokine response in wild-type virus infected
animals in all organs examined; whereas the only changes seen in
MP-12 infected animals were, surprisingly, in the brain. An
increased cytokine response could also be correlated with
histological changes seen in the organs of ZH501 infected animals
versus those infected with MP-12. These studies reinforce the
notion that the pathogenicity seen in RVFV infections in mice is
driven primarily by an unregulated host inflammatory response
which results in significant loss of liver function and development
of neurologic disease.
Methods
Ethics statement
This animal study was conducted in accordance with an animal
use protocol approved by the Institutional Animal Care and Use
Committee (IACUC) (Protocol #0505029) at the University of
Texas Medical Branch (UTMB) following recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. This institution also accepts as mandatory the
PHS policy on Humane Care of Vertebrate Animals used in
testing, research and training. All work was performed at UTMB
in a facility accredited by the American Association for the
Accreditation of laboratory Animal Care.
Cell lines and viruses
RVFV wild-type strain ZH501 and vaccine strain MP-12 were
obtained from Dr. John Morrill (UTMB). The virus stocks used for
the assays described here were p2 (MP-12) and p1 (ZH501) from
the stocks received from Dr. Morrill. Both viruses were cultured
and titrated on Vero E6 cells (ATCC # CRL-1586). For virus
Author Summary
Rift Valley fever virus (RVFV) is a deadly virus that is found
primarily in sub-Saharan Africa. However, mosquitoes that
are capable of transmitting RVFV have a worldwide
distribution. RVF affects a broad range of animal species
and is known to cause encephalitis or hemorrhagic fever in
humans with survivors having long-term health effects
such as a loss of vision. There is no vaccine currently
approved for use in humans. In this study we evaluated
the host response to infection with either a RVFV vaccine
strain or a wild-type strain to identify similarities or
differences that could be exploited for development of
therapeutics or improved vaccines. While mice infected
with the vaccine strain did not develop disease and
survived, infection with the wild-type strain caused severe
disease with a fatal outcome. Analyzing multiple clinical
factors and the host immune response over the course of
infection allowed us to identify potential host factors
associated with disease progression during wild-type virus
infection. This work also provides support for a current
vaccine candidate, MP-12, in demonstrating a limited and
protective host response to infection.
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inoculation.
Mouse challenge studies
Adult (8–10 week old), female C57BL/6 mice (Harlan Sprague
Dawley) were inoculated subcutaneously with 1,000 plaque
forming units (PFU) of ZH501, MP-12 or an equivalent volume
of diluent. The LD50 for ZH501 is ,1 PFU. Each challenge group
consisted of 5 animals. Three challenge groups (one group each:
ZH501, MP-12 and mock infected) were terminally bled and
euthanized every 12 hours post-infection (hpi). Mice from groups
designated for sacrifice on the last day of the experiment had their
weight and body temperature measured daily throughout the
course of the experiment by BioMedic Data Solutions (Seaford,
DE) transponders implanted two days prior to challenge. All work
involving handling of infectious RVFV ZH501, was performed in
the Robert E. Shope BSL-4 laboratory at UTMB.
At sacrifice, whole blood was collected for hematology and
clinical chemistry and serum was isolated for analysis of the
cytokine response profile and for virus titration. Approximately
half of each organ we examined (liver, spleen and brain) was
harvested and homogenized in 0.5 ml PBS using a Qiagen
TissueLyser (Qiagen) to be used for virus titration and cytokine
profile analysis. All samples removed from BSL-4 laboratory were
c-irradiated (5 Mrad) prior to analysis.
Virus titration
Vero E6 cells were infected with 100 ml of sample through 10-
fold serial dilutions. Plates were incubated for 1 hour in a 37uC
incubator with 5% CO2 and gentle rocking every 15 minutes. A
0.8% tragacanth (f/c)/16MEM overlay was applied to the wells.
After 3 days, the overlay was removed and the cells were stained
with 0.2% crystal violet diluted in 10% formalin. The plaques
were counted and the titers determined. Viral titers are reported as
log10 PFU.
Bio-plex assay
Tissue homogenates and serum were processed according to
manufacturer instructions and then analyzed using a Bio-plex 200
system (Bio-Rad, Hercules, CA). Briefly, the samples were
centrifuged for 10 minutes at 1,000 rpm at 4uC to remove debris.
The supernatants were collected and aliquoted into 96-well plates
in pre-determined wells; this plate was centrifuged at 1,250 rpm to
remove any remaining debris. The supernatant was transferred to
a 96-well flat bottom plate and processed for use on the Bio-plex
system. The cytokines were coupled to cytokine specific multi-plex
beads (Bio-Rad) following the manufacturer’s instructions using
pre-designed assays that measured the concentration of a panel of
cytokines including interleukin (IL)-1a/b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12 (p40, p70), IL-13, IL-17, eotaxin, IFNc,
KC (CXCL1), monocyte chemoattractant protein (MCP)-1
(CCL2), granulocyte colony-stimulating factor (G-CSF), granulo-
cyte macrophage colony-stimulating factor (GM-CSF), macro-
phage inflammatory protein (MIP)1a/b (CCL3/CCL4), tumor
necrosis factor (TNF)-a and RANTES (CCL5).
ELISA
Assays for IFN-b were performed by ELISA following the
manufacturer’s instructions (PBL Biomedical Laboratories, Piscat-
away, NJ). Samples were prepared similarly to the Bio-plex
samples. They were centrifuged for 10 minutes at 1,000 rpm at
4uC to remove debris. The supernatant was transferred to ELISA
strips processed for use on the plate reader. The IFN-b in the
sample adhered to the pre-coated wells during incubation. After
washing, the plates were incubated with HRP-conjugated
secondary antibody, with a washing step between incubations.
The strips were then incubated with a TMB solution for
15 minutes and 100 ml of stop solution was added. These strips
were read at 450 nm within 5 minutes of addition of stop solution.
Clinical evaluation
Complete blood counts (CBC) were evaluated with a Hemavet
hematology analyzer (Drew Scientific, Dallas, TX). Analysis
included total white (WBC) and red blood cell (RBC) counts,
platelet counts, hemoglobin concentration, hematocrit, and the
counts of white blood cell subpopulations (lymphocytes, mono-
cytes, eosinophils, neutrophils, and basophils). Clinical chemistry
analysis was performed using a VetScan2 Chemistry Analyzer
(Abaxis, Union City, CA). Fourteen analytes were examined
including the liver enzyme alanine aminotransferase (ALT), serum
glucose, amylase, plasma electrolytes (calcium, phosphorus,
sodium, and potassium), globulin, albumin, total bilirubin, urea
nitrogen, creatinine, and total protein.
Immunohistochemistry (IHC)
Formalin-fixed tissues were processed in a Sakura Tissue-Tek
VIP Processor, and were mounted in paraffin blocks. The RVFV
antigen immunostain was prepared using mouse on mouse
polymer technology and the Sequenza cover plate system. The
steps briefly were: 1) Antigen retrieved using DIVA solution in a
steamer (20 min); 2) Peroxide block using peroxidase (5 Min); 3)
Blocking step using Rodent Block M (30 min); 4) RVFV mouse
hyper-immune ascitic fluid (World Reference Collection for
Emerging Viruses and Arboviruses at UTMB), used at 1:100
dilution (60 min); 6) Secondary antibody using Biocare MM HRP
Polymer (30 min); 7) chromagen was DAB (5 min); 8) Counter-
stained with hematoxylin for 5 minutes.
Statistical analysis
As the test groups are small, a Fisher’s exact test was used to
determine the significance between ZH501, MP-12 and mock
infected groups in clinical and cytokine analyses. A Kaplan-Meier
estimate weight and temperature analysis was applied to the 6 days
post infection (dpi) group.
Results
Clinical observations
As anticipated, mock and MP-12 infected mice showed no signs
of clinical disease and all survived until sacrificed or the end of the
experiment. ZH501 infected mice began to show signs of illness
(i.e. ruffled fur and hunched posture) by 36 hpi. All ZH501
infected mice developed signs of clinical illness and succumbed to
disease. Of the subset of ZH501 infected animals monitored daily
for weight and body temperature, 85% were alive on day 2, 30%
survived to day 3, and all were dead at day 4 (Figure 1). All
animals in the monitored MP-12 and mock-infected groups
survived through completion of the study. During the course of the
experiment, none of the mice lost a significant amount of weight or
became febrile (Figure 2).
Complete Blood Counts (CBCs)
CBCs are an important diagnostic and prognostic tool for
determining overall human clinical health and are a reliable
measure of multiple indices of whole blood components. We
performed CBCs in this study to determine their utility in assessing
the health of mice during RVFV infections. Whole blood from
Cytokine Response to RVFV Infection in the Mouse
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significant difference in the total white blood cell (WBC) count
between mock and MP-12 infected mice was observed for any of
the measured parameters (Figure 3, Table S1). The CBC’s of
ZH501 infected animals were not remarkably different from MP-
12 or mock infected animals until 60 hpi where drop in total WBC
count was observed between 60 and 72 hpi, but rebounded at 84
and 96 hpi. The decrease in total white blood cells between 60 and
72 hpi was driven primarily by marked reduction in lymphocyte
and monocyte numbers in the ZH501 infected animals. At 96 hpi
the concentration of monocytes in ZH501 infected animals was
elevated relative to both mock and MP-12 infected animals, but
the difference was not significant. Eosinophils only showed a
change at 96 hpi after ZH501 infection when the concentration of
eosinophils was increased in ZH501 infected animals. The
neutrophil population did not deviate significantly between the
infection groups over the course of the experiment (Table S1).
RBC populations were largely the same between all three
challenge groups. However, at 24 hpi the RBC concentration in
MP-12 infected animals was significantly higher than in mock or
ZH501 infected mice while at 72 hpi, ZH501 infected animals had
a decreased RBC count (Figure 3, Table S1). Interestingly, the
platelet count was within normal ranges (592–2,972 K/ul) for all
groups until 72 hpi where the platelet concentration in ZH501
infected mice dropped well below normal. There was a slight
recovery at 84 hpi, but then the level dropped to below normal
again at 96 hpi.
Serum chemistry
RVFV is known to be hepatotropic [43] and infection can
stimulate release of liver specific enzymes from disrupted
hepatocytes and serve as clinical markers of hepatic dysfunction.
In this study serum liver enzyme concentrations became elevated
in ZH501 infected mice as the disease progressed. Alanine
aminotransferase (ALT) began to increase at 36 hpi and peaked
in concentration at 60 hpi in ZH501 infected animals (Figure 4C).
While normal values of ALT in the mouse are 17–77 U/L, one
mouse infected with ZH501 had ALT serum levels over 500 U/L
at 36 hpi, one animal had levels of 1,300 U/L at 48 hpi, and two
mice had over 1,500 U/L of ALT in their serum at 60 hpi. No
animals in the mock or MP-12 infected groups had ALT
concentrations above 150 U/L (Figure 4A–B).
Serum glucose levels dropped drastically in ZH501 infected
mice at 72 hpi (Figure 4C), began to increase at 84 hpi, and were
above normal at 96 hpi. Total bilirubin was also elevated in
ZH501 infected animals (Figure 4C). At 72 and 84 hpi one mouse
in each ZH501 infected group had elevated total bilirubin
concentrations. Analyzed plasma electrolytes (calcium, phospho-
rous, sodium, and potassium) did not show a significant deviation
from normal concentrations (data not shown).
Virus distribution
To correlate the onset of illness with virus replication in different
organs, we harvested tissues from groups of 5 mice every 12 hours
and determined virus titers by plaque assay. MP-12 infected
animals did not have any detectable virus in any tissue until they
became viremic at 72 hpi with a peak titer of 2.5 log10 PFU/ml.
The viremia was below detectable limits (,200 PFU) by 84 hpi in
our assay. In the liver, virus appeared at 96 hpi when the viral load
was just under 4 log10 PFU/ml with a slight decrease in tissue titer
at 108 hpi and was no longer detectable at 120 hpi. MP-12 was
not detected in the spleens or brains of infected mice at any point
during the study (Figure 5A). ZH501 appeared at 24 hpi in the
serum and peaked at 84 hpi with over 7 log10 PFU/ml in the liver
(Figure 5B). In the spleen the peak viral titer was seen at 48 hpi
where over 6 log10 PFU/ml of virus was present. While there was
a fall in the spleen titers at 72 hpi, the viral titers in the serum,
liver, and brain remained elevated. ZH501 titers peaked at 60 hpi
in the brain and serum at 5 log10 PFU/ml and 6 log10 PFU/ml,
respectively. Virus titers declined to levels undetectable by plaque
assay in the serum, liver and brain in the three remaining animals
sacrificed at 96 hpi (Figure 5B).
Immunohistochemical stains for RVFV antigen in formalin-
fixed tissues collected from the three study groups were examined
microscopically (Figures 5C–F). RVFV antigen was not found in
Figure 1. Mouse survival after infection. Percent survival of mice
that were infected with vaccine strain MP-12, wild-type strain ZH501 or
were mock infected. Animals included in this figure were from a
predetermined subset of animals that were analyzed for temperature
and weight changes (Figure 2). Of all animals included in this study,
only three ZH501 infected animals survived to 96 hpi. All mock and MP-
12 infected animals survived until euthanized for tissue collection.
doi:10.1371/journal.pntd.0001529.g001
Figure 2. Mouse daily weight and temperature. Daily weight (g)
and temperature (uC) of mock-infected C57BL/6 mice and mice infected
with either MP-12 or ZH501.
doi:10.1371/journal.pntd.0001529.g002
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the study. Seven of 11 MP-12 infected mice had no viral antigen in
any of the tissues examined while three mice, one each at 48, 72,
and 96 hpi, had occasional antigen-positive cells in splenic red
pulp sinusoids and white pulp lymphoid follicles. One MP-12
infected animal at 96 hpi exhibited cytoplasmic antigen staining
within multiple hepatic microgranulomas. Seven of eight ZH501
infected mice sacrificed from 48 to 84 hpi exhibited diffuse
granular cytoplasmic viral antigen staining in most hepatocytes
(75% to 95% of cells affected) (Figures 5C–D). While two of eight
ZH501 infected animals had no splenic viral antigen staining, up
to 5% of the cells in splenic red pulp sinusoids and white pulp
lymphoid follicles in the other six animals contained cytoplasmic
viral antigen (Figure 5E). Viral antigen was not detected in brain
or spinal cord sections in any mouse from any infection group
(Figure 5F).
Cytokine profiles
RVFV infection is known to cause a number of pathogenic
effects that could be correlated with the host immune response to
infection. In order to identify potential mechanisms of pathogen-
esis during RVFV infection, we examined the cytokine response
and histological changes in three major organs (spleen, liver, brain)
and serum. We chose these organs because they are principal
components of the host immune response and have been
associated with RVFV pathogenicity [43,44]. The results from
these assays found that wild-type ZH501 causes a significant
cytokine response in all of the organs examined compared to MP-
12. The responses for each organ are summarized below.
Individual graphs for a representative subset of the cytokines
examined are shown in Figures S1, S2, S3, S4.
Serum (Figure S1). The serum from RVFV infected animals
was evaluated for changes in cytokine levels relative to mock-
infected animals. These studies indicated a mild and limited
inflammatory response in MP-12 infected animals with slight
elevations of IL-6, IL-12 and MIP-1a around 72 hpi. Elevated IL-
12(p70) and IFN-c suggest a Th-1 response against viral infection.
In contrast, the response against ZH501 infection was very broad
with onset evident at 48 hpi with significant elevations of IL-6,
KC, MCP-1 and MIP-1a. By 72 hpi, virtually all cytokines
measured in ZH501 infected animals were significantly elevated
relative to mock infected animals. The concentrations of IL-6, G-
CSF and MCP-1 indicate a strong inflammatory response and
potential response to vascular leakage [45]. Interestingly, the
majority of these cytokines return to non-significant levels in
animals sampled at the 84 hpi time-point although IL-6, IL-8, G-
CSF and MCP-1 remain elevated.
Liver (Figure S2). Liver samples from MP-12 infected
animals showed no significant deviation from mock-infected
control animals with the exception of a decrease of IL-12(p70) at
72 hpi. As with serum samples, liver homogenates from ZH501
infected animals had evidence of an inflammatory response with
increases in KC, MCP-1 and MIP-1a. A number of cytokines,
such as IL-1a, IL-12, G-CSF and KC, became elevated at 48 hpi
with most peaking at 72 hpi. G-CSF and KC concentrations were
both very high with peak concentrations several hundred fold
higher than mock infected controls. MCP-1 and IL-1a were also
elevated although not to the extent of G-CSF and IL-8.
Spleen (Figure S3). The response to MP-12 infection in the
spleen was much like that seen in the serum except that cytokine
peaks were delayed by approximately 24 hpi. As seen in the
serum, IL-6, IL-12(p70) and IFN-c concentrations peaked at levels
that were significantly higher than in mock infected animals. In
ZH501 infected animals, cytokine concentrations began to
increase significantly beginning at 48 hpi. IL-6 and G-CSF had
the largest fold changes, 200 and 450 times higher, respectively,
Figure 3. Hematology results. Total white blood cell, lymphocyte, red blood cell and platelet counts over the course of disease in mock (e), MP12
( ) or ZH501 (m) infected animals. Each data point represents the mean of 5 animals per group except at 96 hpi in the ZH501 group where only 3
animals remained.
doi:10.1371/journal.pntd.0001529.g003
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concentrations of IL-2, IL-4, IL-12(p70) or IFN-c suggesting that
there was little, if any, stimulation of T- or B-cell activation or
differentiation in the spleen. However, significant induction of IL-
6, IL-1a, and several chemokines, particularly MCP-1, indicates
recruitment of pro-inflammatory cells into the spleen. The peak
cytokine response in the spleen (72 hpi) correlates with a
significant drop in viral titer in the spleen (see Figure 4B).
Brain (Figure S4). The cytokine response in the brain
indicates that the brain is involved during infection with both
MP-12 and wild-type ZH501. This is particularly interesting given
that we did not detect any virus in the brain of MP-12 infected
animals by plaque assay (Figure 4A) nor were there any signs of
neurologic disease. In MP-12 infected animals, IL-2, IL-13 and IL-
17 were all elevated along with MCP-1 and MIP-1a. The presence
of IL-2, IL-13 and IL-17 suggests the presence and activation of a
B-cell response [46,47]. MCP-1 and MIP-1a concentrations were
elevated soon after infection indicating early onset recruitment of
immunomodulatory cells. The brains of ZH501 infected mice
showed an early response similar to that seen in MP-12 infected
animals, however, concentrations of these cytokines remained
elevated and many of their downstream cytokines also became
elevated with peak concentrations seen at 60–72 hpi. IL-6 was not
evident in the brains of MP-12 infected animals and IL-8 did not
deviate significantly from mock infected animals. In ZH501
infected animals both cytokines were elevated significantly
indicating a strong pro-inflammatory response. G-CSF levels
were also extremely high 48–72 hpi (over 2,500 times higher than
mock and MP-12 infected mice) suggesting stimulation of a strong
protective anti-apoptotic response in the brain that is also
associated with neurogenesis [48–50]. Although there was no
clear clinical or histological evidence that the ZH501 infected
animals developed neurologic disease, the cytokine response
strongly suggests that they were going down a path that could
lead to encephalitis.
IFN-b (Figure 6)-As wild-type RVFV has been shown to have
type I IFN antagonist properties [30,31,34], we examined IFN-b
production in the liver, spleen and brain. One ZH501 infected
animal had elevated IFN-b in the brain at 84 hpi. Three mock
infected animals had slightly elevated IFN-b concentrations in the
brain while none of the other mock infected animals exceeded
75 pg/ml in any sample tested. Similar results were seen in MP-12
infected animals, but one animal had elevated IFN-b in the liver at
36 hpi. However, ZH501 infected animals had elevated IFN-b in
the liver and spleen of the majority of animals tested at 72 and
84 hpi. Mean concentrations of IFN-b in the spleens of ZH501
infected mice were significantly higher (2–5 fold increase) than
both mock and MP-12 infected animals between 48–96 hpi, while
in the liver a significant difference was only seen at 72 hpi.
Histopathology
Examination of H&E stained sections from the liver, spleen and
brain largely supported clinical and cytokine response observations
indicating significant damage to the liver and spleen of ZH501
Figure 4. Liver function enzymes. Alanine aminotransferase (ALT), glucose, and total bilirubin concentrations in the serum of mock (A), MP-12 (B)
and ZH501 (C) infected mice. The first row provides serum ALT concentrations, the second row glucose concentrations and the third total bilirubin
concentrations. Each symbol represents an individual mouse. There were five mice in each group, except at 96 hpi where only three animals had
survived until this point of the study. The horizontal bar represents the mean of the mice for that group. Please note that the maximum for the Y-axis
in (C)-ALT is 2000 U/L rather than 150 U/L as in (A) and (B) ALT graphs.
doi:10.1371/journal.pntd.0001529.g004
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animals were essentially normal (Figures 7 A, B, D, E).
Histological evidence of hepatocellular degeneration and
necrosis was seen as early as 48 hpi in ZH501 infected mice,
and was present throughout the remaining course of the infection.
These findings correlated well with the cytokine response in that
ZH501 infected animals with the more significant cytokine
response also had increased tissue damage. At 48 hpi, the mouse
with the highest cytokine levels (IL-1a, IL-6, IL-8, IL-12, IFNc,
eotaxin, and G-CSF) also exhibited moderate diffuse hepatic
necrosis. Liver changes in the mouse with lower cytokine levels at
48 hpi were much less severe and consisted of diffuse cytoplasmic
vacuolation of hepatocytes and random small microgranulomas.
At 60 hpi, the mouse with higher levels of IL-1a, IL-6, IL-8, IFNc,
Figure 5. Viral Titers. Viral titers in the serum, liver, spleen, and brain after infection with (A) MP-12 or (B) ZH501. Each point with the exception of
96 hpi in the ZH501 graph represents the mean virus titer of five mice. The 96 hpi points in the ZH501 graph represent only the 3 mice that survived
until that point. Error bars for the standard deviation were removed for clarity. (C) Immunohistochemical staining for RVFV antigen in liver from a
ZH501 infected mouse at 60 hpi. Intracytoplasmic viral antigen is depicted by brown staining, 106. (D) Immunohistochemical stain of liver from a
ZH501 infected mouse at 84 hpi. Intracytoplasmic viral antigen is depicted by brown staining, 206. (E) Immunohistochemical stain of spleen for RVFV
antigen from a ZH501 infected mouse at 84 hpi. The red pulp sinusoids contain numerous cells with cytoplasmic brown, granular material depicting
viral antigen. There are no viral antigen positive cells in the lymphoid follicle. Note the increased lymphocytolysis depicted by pyknotic nuclei and
cellular fragments, 206. (F) Brain from a ZH501 infected animal at 84 hpi with no pathologic changes, H&E 2.56.
doi:10.1371/journal.pntd.0001529.g005
Cytokine Response to RVFV Infection in the Mouse
www.plosntds.org 7 February 2012 | Volume 6 | Issue 2 | e1529and various chemokines in the liver had moderate necrosis and
hepatocyte degeneration, while other ZH501 infected animals had
minimal microgranulomas composed of neutrophils, Kupffer cells,
and lymphocytes that did not affect surrounding tissue. The foci of
hepatocyte degeneration and necrosis contained occasional
neutrophils, Kupffer cells and lymphocytes. At 72 hpi, the livers
of ZH501 infected mice had evidence of severe architectural
disruption and most of the hepatocytes were in the process of
degeneration and necrosis. There was disassociation of hepato-
cytes from hepatic plates, expansion of sinusoidal lumens and
accumulation of blood (hemorrhage) within dilated hepatic
sinusoids. Most of the hepatocyte nuclei that remained intact
contained a single, centrally-located, intranuclear eosinophilic
inclusion that tended to peripheralize the nuclear chromatin. At
84 hpi, the livers looked similar to those collected at 72 hpi with
marked architectural disruption and necrosis (Figure 6C).
The spleens of the mock and MP-12 infected mice remained
essentially normal throughout the study (Figures 7D, E). The only
pathologic changes occurred in mice infected with ZH501. From
48 hpi to 84 hpi, the spleens of ZH501 infected mice with the
highest levels of cytokines (IL-1a,I L - 1 b, IL-6, eotaxin, MCP, and
MIP-1a) also had corresponding splenic enlargement and
moderate amounts of necrotic cellular debris diffusely within
red pulp sinusoids. Similar splenic changes were not seen in
animals with a limited cytokine response. At later time points (i.e.
72 and 84 hpi), however, splenic pathology was more profound,
consisting of increased neutrophilic and histiocytic infiltrates
admixed with hemosiderin and necrotic cellular debris
(Figures 7F).
The brains of all mice appeared essentially normal throughout
the course of the study despite evidence of a high viral titer and
significantly increased inflammatory cytokine concentrations in the
brain tissue of some study animals.
Discussion
Rift Valley fever virus is a highly pathogenic virus that causes
large scale outbreaks in livestock with frequently associated
epidemics in humans. The mouse is an established model for
RVFV infection where animals succumb to wild-type RVFV
infection within a matter of days with disease characteristics
similar to that seen in fatal cases of human disease and in infected
newborn lambs [12]. While the mouse is an accepted model for
disease, the host response to infection has not been well
characterized. Some studies have evaluated clotting time,
mortality, and disease progression, but few have focused in on
the hostimmune response to RVFV infection [12,22,32–35,51–53].
Smith et al. recently described the pathogenesis of wild-type ZH501
infection in BALB/c mice following subcutaneous challenge [35],
but did not have the benefit of cytokine profiles to correlate
pathogenesis to the host response while other studies focused on a
limited number of cytokines [32–34].
The study described here is the first broad examination of the
host response to RVFV infection in the mouse model. This study
Figure 6. IFN-b concentration following infection. IFN-b concentration in the (A) liver, (B) spleen, and (C) brain in mice after infection. The first
row represents mock infected mice, the second row represents MP-12 infected mice, and the third is ZH501 infected mice. Each symbol represents an
individual mouse. There were five mice in each group with the exception of the 96 time-point for ZH501 when only three animals were surviving. The
horizontal bar represents the mean of the mice for each group. Brackets indicate that the average value for ZH501 infected animals is significantly
different from both mock and MP-12 infected animals.
doi:10.1371/journal.pntd.0001529.g006
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www.plosntds.org 8 February 2012 | Volume 6 | Issue 2 | e1529Figure 7. Liver and spleen pathology. (A) Liver from a mock-infected mouse at 84 hpi. The liver is essentially normal H&E 206. (B) Liver from an
MP-12 infected mouse at 84 hpi. The random, small microgranulomas composed of individually-necrotic hepatocytes surrounded by small numbers
of neutrophils and mononuclear cells are unrelated to the study, H&E 206. (C) Liver from a ZH501 infected mouse at 84 hpi, showing piecemeal
hepatocyte necrosis (white arrowhead), hepatocellular intranuclear eosinophilic inclusions (white arrow). Note the presence of neutrophils (black
arrow) within foci of necrosis, H&E stain 406. (D) Spleen from a mock-infected mouse at 84 hpi. The spleen is essentially normal, H&E 206. (E) Spleen
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infection with wild-type ZH501 or the live-attenuated vaccine
strain MP-12 and clearly demonstrates that a significant and
systemic pro-inflammatory immune response is likely a major
contributor to the progression to lethal disease.
Unlike previous studies where we have evaluated the clinical
response to viral infection in the mouse model [54], clinical
analysis of RVFV infection in the mouse provided indicators of
disease onset and development that correlated with reports of
RVFV infection in both humans and primates. In the present
study, there was no statistical difference in body weight or
temperature in any of the challenge groups despite the ZH501
infected animals showing clear indications of disease and
individual animals in the dpi 3 and 4 ZH501 infected groups
losing weight. However, hematological analysis made it clear that
wild-type RVFV infection stimulates depletion of lymphocytes,
monocytes and platelets over the course of disease. The depletion
of total WBC was largely the result of lymphopenia during the
mid-stages of disease in ZH501 infected animals. Our study found
a decrease in both total WBC and lymphocytes between 48 and
60 hpi in ZH501 infected mice (Table S1) with a gradual recovery
toward the end of the study. Lymphocyte recovery may be the
result of stimulation of the hematopoietic system as significantly
increased concentrations of G-CSF were found in the serum and
tissues of ZH501 infected animals. Hematology results in the
C57BL/6 mouse model correlate well with previously published
studies in BALB/c mice [35] and rhesus macaques [52]. Infected
macaques had an initial leukocytosis and then a sharp decrease to
leukopenia at 5 dpi that slowly resolved by 7 dpi. In another study
evaluating WBC counts in ZH501 infected rhesus macaques,
animals with a fatal outcome had evidence of leukocytosis at 2 dpi
which remained elevated until death or returned to baseline levels
just prior to death [53]. Animals which showed clinical illness but
survived infection had only a transient leukocytosis.
The decrease in platelet concentration in ZH501 infected mice
was not surprising given the hemorrhagic nature of the disease.
Morrill et al. reported a drop in platelet counts in RVFV infected
macaques which was in direct proportion to the severity of the
disease [53]. In our mouse studies there was no difference between
MP-12 and mock infected animals, but there was a significant
decrease in the mean platelet count in ZH501 infected animals
relative to mock infected animals. Examination of individual
ZH501 infected animals found that mice with liver damage
indicated by elevated serum ALT, low glucose and high bilirubin
also had low platelet counts. However, not all mice with low
platelet counts had evidence of severe liver damage. These data
indicate a correlation between liver disease and low platelet
counts, but not the reverse, in mice infected with wild-type RVFV.
Similar results have been seen in humans where approximately
half of the patients with laboratory confirmed RVF present with
abnormal platelet counts [55].
Clinical chemistry data provided a clear indication of liver
disease in ZH501 infected animals, but no evidence of similar
disease in MP-12 or mock infected animals. Liver necrosis has
been shown to be a large contributor to the mortality seen after
infection with wild-type RVFV [11,35,53,55–57]. In studies with
ZH501 infected non-human primates, serum aminotransferases
were increased in animals with fatal infections [58]. The same
study also showed a correlation between the amount of liver
damage (using ALT values) and viremia [58]. ZH501 infected
mice with elevated ALT and bilirubin concentrations had
histological evidence of hepatitis, liver necrosis and possible
hepatitis associated jaundice. In Saudi Arabia, 95% of patients
with confirmed RVFV infections had increased ALT levels and
75% resulted in liver failure [55]. Animals with extremely elevated
(above 600 U/L) serum ALT also had increased virus titers and a
stronger cytokine response in the liver indicating a strong
correlation with the onset of liver disease. At necropsy the livers
were enlarged, appeared congested, and had areas of black
discoloration. Microscopic examination revealed hepatic necrosis,
loss of sinusoidal integrity, hemorrhage, and significant levels of
viral antigen (Figure 7C).
To characterize the host immune response to RVFV infection
and to differentiate infection with MP-12 vaccine strain from wild-
type ZH501, we determined the concentration of a panel of
cytokines in tissue homogenates and serum. The response to
ZH501 infection was significant and dramatic in all of the tissues
tested while the response to MP-12 infection was largely
unremarkable. The response seen in livers from ZH501 infected
animals was unexpected. Given the nature of the wild-type RVFV
infection, we expected evidence of a significant inflammatory
response in the liver. The induction of a pro-inflammatory
response was not evident; however, a significant chemokine
response focused on recruitment of T-cells, neutrophils and
monocytes was pronounced. Histological evaluation of livers from
ZH501 infected mice identified significant cellular infiltration and
congestion with the appearance of neutrophils, macrophages, and
lymphocytes within disrupted sinusoids and eosinophilic intranu-
clear inclusions that are reported to be characteristic of RVFV
infection [59]. Histological data correlated strongly with the
observed chemokine response and were also consistent with studies
in BALB/c mice [35].
Morphologically, the spleen was enlarged and the red pulp
contained accumulations of cellular debris, neutrophils and
macrophages containing hemosiderin (Figure 7C). Hemosiderin
is commonly found in macrophages when they break down
hemoglobin and release heme and bilirubin after conditions that
result in hemorrhage [60,61]. The presence of hemosiderin
containing macrophages in the spleen is indicative of hemorrhage
following ZH501 infection.
The level of serum cytokines was significantly increased in
ZH501 infected animals. The levels of IL-6, IL-12(p40), G-CSF
and several chemokines were elevated indicating the onset of a
strong inflammatory response and recruitment of immunomodu-
latory cells. The concentrations of all analytes, with the exception
of IL-5 and IL-13, were significantly elevated in serum at 72 hpi,
supporting our hypothesis of a strong unregulated immune
response following ZH501 infection. Interestingly, animals sam-
pled at 84 hpi did not have this broad cytokine response and
animals sampled at 96 hpi had normal cytokine levels. These data
suggest that there might be a critical transition period for RVFV
pathogenesis that occured around 72 hpi, although exactly what
this transition entails or the associated mechanism is unclear.
Despite a slight cytokine response in the brain following MP-12
infection, which could indicate initiation of cellular recruitment,
correlating pathology was not seen. The results from MP-12
infected animals were in striking contrast to the response seen in
ZH501 infected mice. A very significant pro-inflammatory
cytokine response was stimulated in the brains of ZH501 infected
mice and it was maintained through the course of disease. Despite
from an MP-12 infected mouse at 84 hpi. The spleen is essentially normal, H&E 206. (F) Spleen from a ZH501 infected mouse at 84 hpi with moderate
amounts of necrotic cellular debris and macrophages containing hemosiderin (brown pigment) within red pulp sinusoids, H&E 106.
doi:10.1371/journal.pntd.0001529.g007
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beginning around 48 hpi, we did not find viral antigen or
histological evidence of meningoencephalitis as was observed in
BALB/c mice [35]. It is surprising that we could not detect viral
antigen in brain sections, as viral titers reached 5 logs in the brain
when evaluated via plaque assay. Since animals were not perfused
prior to tissue harvest, infectious virions could originate from
residual blood in the brains. Smith et al. [35] did not detect
meningoencephalitis until day 8 post infection while in our study
none of the ZH501 infected animals survived beyond 4 dpi, in
part by experimental design. Based on the Smith et al. study and
observations during vaccine trials, it is likely that the C57BL/6
mice would have developed neurological disease had they survived
longer.
Previously published studies have shown that the NSs protein of
wild-type RVFV has type I IFN antagonist properties [34], while
the MP-12 vaccine strain induces type I IFN in in-bred mouse
strains [30,31,62]. Here we found that wild-type ZH501 induced a
modest IFN-b response in the liver and spleen while the IFN-b
response in MP-12 infected animals was negligible. The induction
of the IFN-b response was not evident until 72 hpi suggesting that
production of measurable IFN-b could be correlated to increases
in virus titer and is similar to results reported by van Vuren in
BALB/c mice [33]. Previous work has shown that the initial
inhibition of type I IFN occurs shortly after infection allowing the
virus to become established with the resulting release of IFN-b
coming from bystander cells [30,31]. These data are similar to
results from Bouloy et al who found that acid stable IFN-a/b levels
were negligible in the serum of wild-type (129/SvPasIco) mice
infected with either wild-type ZH548 virus or the MP-12 virus
[31]. The lack of a strong generalized immune response suggests a
key localized role for IFN-b at the very onset of viral infection of
macrophages or dendritic cells which could limit virus propagation
and dissemination, subsequently eliminating the induction of a
broad response. Evidence of virus in the spleen of some MP-12
infected animals and the moderate Th-2 type response in the brain
suggests that some virus escapes initial control measures, but that
the particle numbers are insufficient to trouble a competent
immune system.
In this study, we have clearly identified significant host
response differences in the mouse model following infection with
either wild-type RVFV or the attenuated vaccine strain. We have
also identified a temporal correlation between increased virus
titers in ZH501 infected mice, a decrease in lymphocytes,
monocytes and platelets, architectural disruption and necrosis
in the liver, and the onset of a significant systemic cytokine
response. The specific mechanisms driving these physiological
changes still need to be elucidated. However, many of the
responses that we identified can be directly correlated to disease
outcome. Clearly, there is a significant amount of cellular
infiltration into and necrosis of the liver that likely limits organ
function, disrupts regulation of the acute phase response and the
ability of the coagulation cascade to limit hemorrhaging,
regardless of the mechanism associated with vascular leakage.
There is also evidence that neurologic disease may play a role in
the demise of ZH501 infected animals despite a lack of gross signs
of neurologic disease. The finding of neurologic involvement is
not surprising as we have observed a number of studies with
vaccines and attenuated viruses where animals that survive the
first phase of disease following ZH501 infection and are only
partially protected may succumb to neurologic disease 10–14 dpi
(M. Holbrook, unpublished observations). There have also been
published reports of humans developing neurologic [63] and
ocular disease [64,65] as a result of RVFV infection.
This study has demonstrated that RVFV vaccine strain MP-12
infects and replicates in adult C57BL/6 mice, but does not cause
acute disease, while the wild-type strain ZH501 is highly
pathogenic and causes a significant innate immune response.
Given that there are only 11 amino acid differences between the
MP-12 strain and ZH548, and the high homology between
ZH501 and ZH548, the differences in the host response are quite
impressive. This study further validates the use of the mouse as a
model for RVFV infection as clinical and immune response
parameters can be correlated between the mouse and human
disease. These studies also support the use of MP-12 as a safe and
effective vaccine and on-going clinical trials will hopefully provide
additional incentive for the use of MP-12 as a vaccine for RVFV.
Supporting Information
Figure S1 Serum cytokines. The concentration of key
cytokines in the serum of mice after mock infection or infection
with MP-12 or ZH501. Shown here are the changes in actual
concentration [pg/ml] of individual cytokines. Columns marked
with a (#) indicate a significant change between MP-12 and mock
infected mice. Columns marked with an (*) indicate a significant
change between ZH501 infected and mock infected mice, while
columns marked with a (+) indicate a significant difference
between MP-12 and ZH501 infected animals. The numbers are
the average of 5 mice 6 the standard deviation between the mice
except 96 hours post ZH501 infection, where only 3 surviving
mice are represented.
(TIF)
Figure S2 Liver cytokines. The concentration of key
cytokines in the liver of mice after mock infection or infection
with MP-12 or ZH501. Shown here are the changes in actual
concentration [pg/ml] of individual cytokines. Columns marked
with a (#) indicate a significant change between MP-12 and mock
infected mice. Columns marked with an (*) indicate a significant
change between ZH501 infected and mock infected mice, while
columns marked with a (+) indicate a significant difference
between MP-12 and ZH501 infected animals. The numbers are
the average of 5 mice 6 the standard deviation between the mice
except 96 hours post ZH501 infection, where only 3 surviving
mice are represented.
(TIF)
Figure S3 Spleen cytokines. The concentration of key
cytokines in the spleen of mice after mock infection or infection
with MP-12 or ZH501. Shown here are the changes in actual
concentration [pg/ml] of individual cytokines. Columns marked
with a (#) indicate a significant change between MP-12 and mock
infected mice. Columns marked with an (*) indicate a significant
change between ZH501 infected and mock infected mice, while
columns marked with a (+) indicate a significant difference
between MP-12 and ZH501 infected animals. The numbers are
the average of 5 mice 6 the standard deviation between the mice
except 96 hours post ZH501 infection, where only 3 surviving
mice are represented.
(TIF)
Figure S4 Brain cytokines. The concentration of key
cytokines in the brain of mice after mock infection or infection
with MP-12 or ZH501. Shown here are the changes in actual
concentration [pg/ml] of individual cytokines. Columns marked
with a (#) indicate a significant change between MP-12 and mock
infected mice. Columns marked with an (*) indicate a significant
change between ZH501 infected and mock infected mice, while
columns marked with a (+) indicate a significant difference
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www.plosntds.org 11 February 2012 | Volume 6 | Issue 2 | e1529between MP-12 and ZH501 infected animals. The numbers are
the average of 5 mice 6 the standard deviation between the mice
except 96 hours post ZH501 infection, where only 3 surviving
mice are represented.
(TIF)
Table S1 Complete blood cell counts. Total white blood
cell concentration (WBC), lymphocyte concentration (LY), mono-
cyte concentration (MO), eosinophil concentration (EO), neutro-
phil concentration (NE), total red blood cell concentration (RBD)
and platelet concentration (PLT) after mock, MP-12 or ZH501
infection. Each value is the average of 5 mice with the standard
deviation (SD) below, except 96 hpi in the ZH501 infected group
which represents the average of the three surviving mice. K/
ml=103 cells/ml; M/ml=106 cells/ml. *Note: n=5 for all time
points except 96 hours post ZH501 infection where n=3. A subset
of these data are presented in Figure 3.
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